'Unmet Needs And Thinking Big,' Inari Buys LimFlow For $250m To Add CLTI Treatment
Executive Summary
LimFlow recently earned FDA approval for its transcatheter deep-vein arterialization system for the treatment of chronic limb-threatening ischemia. Inari, which has previously focused on venous thromboembolism, believes LimFlow's total addressable market could be worth over $4bn annually, with no direct competition in sight.
You may also be interested in...
Cardiovascular Catch-Up: Philips New AI Finds AF Needle In ECG Haystack; LimFlow Moves Closer To US Approval
Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small. Part two of this month's installment includes updates from lesser-known companies that you might have missed, including Cardiologs, Rhythm Management, LimFlow and ShockWave.
R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial
An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.
LimFlow On Target For 2021 US Launch Of Deep Vein Arterialization System
The results from the PROMISE I feasibility study give LimFlow confidence that the PROMISE II pivotal trial will prove that the LimFlow percutaneous deep vein arterialization system is a safe and effective alternative to amputation for patients with critical limb ischemia.